IKS Health Overtakes Titan as Most Valuable Holding in Rekha Jhunjhunwala’s Portfolio
Mumbai, India – In a major portfolio reshuffle, Rekha Jhunjhunwala, wife of the late Rakesh Jhunjhunwala, has significantly reduced her stake in Titan Company Ltd., a key Tata Group subsidiary, while increasing her holdings in Inventurus Knowledge Solutions (IKS) Health. For the first time in nearly two decades, Titan is no longer the most valuable holding in the Jhunjhunwala portfolio.
According to data from Ace Equities, the total value of the Jhunjhunwala family’s stake in Titan has declined from ₹17,481 crore at the end of the September quarter to ₹14,741 crore by the December quarter of FY 2025. IKS Health has now emerged as the largest holding in the portfolio, with a holding value of ₹16,319 crore.
Titan Stake Reduced Amid Market Correction
Jhunjhunwala Family’s Titan Holdings Drop 15% in Value
Titan, a long-time favorite in the Jhunjhunwala portfolio, has seen a 15% decline in the value of its holdings, largely due to market corrections.
- As of December 31, 2024, the Jhunjhunwala family’s total stake in Titan stood at 5.14%, equivalent to 4,57,13,470 shares.
- The stock, which peaked at ₹3,800 per share, has declined by approximately 15%, bringing it close to its 52-week low.
- The family first invested in Titan in 2002 when the stock was trading at an adjusted price of ₹4 per share.
Analyst sentiment remains mixed:
- 34 analysts currently cover Titan.
- 17 analysts recommend a ‘Buy’,
- 12 suggest ‘Hold’,
- 5 have given a ‘Sell’ rating.
The sharp decline in the Titan holding suggests a strategic reallocation of the Jhunjhunwala family’s portfolio.
IKS Health Takes the Lead: A New Portfolio Star
IKS Becomes the Most Valuable Stock in the Jhunjhunwala Portfolio
Inventurus Knowledge Solutions (IKS) Health, a healthcare technology and outsourcing firm, has now overtaken Titan as the most valuable asset in Rekha Jhunjhunwala’s investment portfolio.
IKS was listed on the National Stock Exchange (NSE) in December 2024, with an initial price band of ₹1,329 per share.
- The stock hit an all-time high of ₹2,190 on December 26, 2024.
- Its lowest price was ₹1,559 on January 28, 2025.
- The stock currently trades at ₹1,651 per share, maintaining strong investor interest.
What is IKS Health?
IKS Health operates as a Platform as a Service (PaaS) provider specializing in the U.S. healthcare sector. The company helps healthcare providers outsource administrative tasks, allowing physicians to focus on patient care.
ICICI Securities recently named IKS Health as a top pick, citing:
- Strong financial performance
- Advanced technology capabilities
- A large-scale opportunity in the U.S. healthcare market
The brokerage has issued a ‘Hold’ rating on IKS, with a target price of ₹1,820 per share, based on a valuation of 35x FY2027 earnings per share (EPS).
Other Notable Portfolio Movements
Fortis Healthcare, Indian Hotels, and Star Health See Value Gains
While Titan saw a reduction in value, the Jhunjhunwala family’s holdings in Fortis Healthcare, Indian Hotels, and Star Health & Allied Insurance saw an increase in value.
Meanwhile, no major changes were observed in other large holdings such as:
- Metro Brands
- Tata Motors
- NCC Ltd.
Market Implications & Future Strategy
The shift from Titan to IKS Health signals a major portfolio realignment, possibly driven by:
- Diversification beyond traditional stocks like Titan.
- Increased focus on high-growth technology and healthcare sectors.
- Strategic profit-booking in legacy holdings amid market volatility.
As Titan remains near its 52-week low, it remains to be seen whether the Jhunjhunwalas will further reduce their stake or re-enter at lower levels. Meanwhile, IKS Health continues to gain investor attention, reinforcing its position as a high-growth stock in the healthcare sector.
